A review of pediatric uveitis: Part II. Autoimmune diseases and treatment modalities

Journal of Pediatric Ophthalmology and Strabismus

Volumn 45, Issue 4, 2008, Pages 202-219

  Madigan, William P ^a   Raymond, William R ^b   Wroblewski, Keith J ^c   Thebpatiphat, Nuthida ^a   Birdsong, Richard H ^d   Jaafar, Mohamad S ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b MADIGAN ARMY MEDICAL CENTER   (United States)

^c NATIONAL EYE INSTITUTE   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ALEMTUZUMAB; ALPHA INTERFERON; AZATHIOPRINE; CALCIUM; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DAPSONE; EFALIZUMAB; ETANERCEPT; FLUOCINOLONE ACETONIDE; FOLIC ACID; GROWTH HORMONE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MULTIVITAMIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYDRIATIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RAPAMYCIN; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; ZENEPAX;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACNE; ADJUVANT THERAPY; ALOPECIA; AUTOIMMUNE DISEASE; AZOOSPERMIA; BEHCET DISEASE; BIOENGINEERING; BONE DENSITY; BONE MARROW SUPPRESSION; CARDIOMYOPATHY; CENTRAL NERVOUS SYSTEM; CHILD; CHRONIC DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CRYOTHERAPY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; FILTERING OPERATION; GASTROINTESTINAL SYMPTOM; GONAD DYSFUNCTION; GROWTH RETARDATION; HEMORRHAGIC CYSTITIS; HISTOPLASMOSIS; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION; INFLAMMATION; INTERMEDIATE UVEITIS; INTERSTITIAL NEPHRITIS; INTERSTITIAL PNEUMONIA; IRIDOTOMY; JUVENILE RHEUMATOID ARTHRITIS; KERATITIS; KIDNEY CARCINOMA; LASER COAGULATION; LETHARGY; LEUKOPENIA; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG FIBROSIS; METASTASIS; MONOTHERAPY; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEPHROTOXICITY; OBESITY; OSTEOLYSIS; RETROBULBAR OPTIC NEUROPATHY; REVIEW; RISK FACTOR; SARCOIDOSIS; SIDE EFFECT; SMALL CELL CARCINOMA; SPONDYLOARTHROPATHY; SYMPATHETIC OPHTHALMIA; THROMBOCYTOPENIA; TRABECULOTOMY; UVEITIS; VOGT KOYANAGI SYNDROME;

ADOLESCENT; AUTOIMMUNE DISEASES; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; UVEITIS;

EID: 51349159318     PISSN: 01913913     EISSN: None     Source Type: Journal    
DOI: 10.3928/01913913-20080701-10     Document Type: Review

References (150)

1. Cunningham ET Jr. Uveitis in children. Ocul Immunol Inflamm. 2000;8:251-261.
2. Päivönsalo-Hietanen T, Tuominen J, Saari KM. Uveitis in children: population-based study in Finland. Acta Ophthalmol Scand. 2000;78:84-88.
3. Rothova A, Suttorp-van Schulten MS, Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332-336.
4. de Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol. 2003;87:879-884.
5. Tugal-Tutkun I, Havrlikova K, Power WJ, Foster CS. Changing patterns in uveitis of childhood. Ophthalmology. 1996;103:375-383.
6. Andersson Gäre B. Juvenile arthritis: who gets it, where and when? A review of current data on incidence and prevalence. Clin Exp Rheumatol. 1999;17:367-374.
7. Weiss JE, Ilowite NT. Juvenile idiopathic arthritis. Pediatr Clin N Am. 2005;52:413-442.
8. Petty RE, Southwood TR, Baum J, et al. Revision or the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol. 1998;25:1991-1994.
9. Cassidy JT, Levinson JE, Bass JC, et al. A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum. 1986;29:274-281.
10. Ansell BM. Juvenile spondylitis and related disorders. In: Moll JMH, ed. Ankylosing Spondylitis. Edinburgh: Churchill Livingstone; 1980:120.
11. Schneider R, Passo MH. Juvenile rheumatoid arthritis. Rheum Dis Clin North Am. 2002;28:503-530.
12. Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33:251-255.
13. Petty RE, Cassidy JT, Sullivan DB. Clinical correlates of anti-nuclear antibodies in juvenile rheumatoid arthritis. J Pediatr. 1973;83:386-389.
14. Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003;121:437-440.
15. Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFα agents J Pediatr. 2006;149:833-836.
16. Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology. 2006;45:982-989.
17. Park SH, Park KS, Seo YI, et al. Association of MICA polymorphism with HLA-B51 and disease severity in Korean patients with Behçet's disease. J Korean Med Sci. 2002;17:366-370.
18. Michelson JB, Chisari FV. Behçet's disease. Surv Ophthalmol. 1982;26:190-203.
19. Dedeoglu F, Sundel RP. Vasculitis in children. Pediatr Clin N Am. 2005;52:547-575.
20. Atmaca LS. Fundus changes associated with Behçet's disease. Graefes Arch Clin Exp Ophthalmol. 1989;227:340-344.
21. Sakane T, Takeno M. Current therapy in Behçet's disease. Skin Therapy Lett. 2000;5(6):3-5.
22. Lee JY, Chao SC, Yang MH, Yan JJ. Sarcoidosis in Taiwan: clinical characteristics and atypical mycobacteria. J Formos Med Assoc. 2002;101:749-755.
23. Judson MA, Thompson BW, Rabin DL, et al. The diagnostic pathway to sarcoidosis. Chest. 2003;123:406-412.
24. Hoover DI, Khan JA, Giangiacomo J. Pediatric ocular sarcoidosis. Surv Ophthalmol. 1986;30:215-228.
25. Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145:234-241.
26. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. 1997;336:1224-1234. Erratum in: N Engl J Med. 1997;337:139.
27. Statement on Sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WMOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736-755.
28. Fauroux B, Clement A. Paediatric sarcoidosis. Paediatr Respir Rev. 2005;6:128-133.
29. Baughman AD. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:70-74. Erratum in: Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:310.
30. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis: Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342:763-769.
31. Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest. 2005;128:1062-1067.
32. Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol. 1987;103:234-235.
33. Giles CL. Uveitis in childhood. In: Tasman W, Jaeger EA, eds. Duane's Clinical Ophthalmology. Philadelphia: J. B. Lippincott; 1981:1-8.
34. de Boer J, Berendschot T, van der Does P, Rothova A. Long-term follow-up of intermediate uveitis in children. Am J Ophthalmol. 2006;141:616-621.
35. Henderly DE, Genstler AJ, Smith RE, Rao NA. Changing patterns of uveitis. Am J Ophthalmol. 1987;103:131-136.
36. Raja SC, Jabs DA, Dunn JP, et al. Pars planitis: clinical features and class II HLA associations. Ophthalmology. 1999;106:594-599-659.
37. Oruc S, Duffy BF, Mohanakumar T, Kaplan HJ. The association of HLA class II with pars planitis. Am J Ophthalmol. 2001;131:657-659.
38. Nussenblatt RB, Palestine AG. Intermediate uveitis. In: Uveitis: Fundamentals and Clinical Practice. Chicago: Yearbook Medical; 1989:279.
39. Pulido JS, Meiler WF, Walton D, et al. Results of peripheral laser photocoagulation in pars planitis. Trans Am Ophthalmol Soc. 1998;96:127-141.
40. Jones NP. Fuch's heterochromic uveitis: a reappraisal of the clinical spectrum. Eye. 1991;5:649-661.
41. Scott RA, Sullivan PM, Aylward GW, Pavésio CE, Charteris DG. The effect of pars plans vitrectomy in the management of Fuchs heterochromic cyclitis. Retina. 2001;21:312-316.
42. Jones NP. Extracapsular cataract surgery with and without intraocular in Fuchs' heterochromic cyclitis. Eye. 1990;4:145-150.
43. Quentin CD, Reiber H. Fuchs heterochromic cyclitis: rubella virus antibodies and genome in aqueous humor. Am J Ophthalmol. 2004;138:46-54.
44. de Groot-Mijnes JD, de Visser L, Rothova A, Schuller M, van Loon AM, Weersink AJ. Rubella virus is associated with Fuchs heretochromic iridocyclitis. Am J Ophthalmol. 2006;141:212-214.
45. Posner A, Schlossman A. Syndrome of unilateral recurrent attacks of glaucoma with cyclitic symptoms. Arch Ophthalmol. 1948;39:517-535.
46. Jap A, Sivakumar M, Chee AP. Is Posner Schlossman syndrome benign? Ophthalmology. 2001;108:913-918.
47. Raitta C, Vannas A. Glaucomatocyclitic crisis. Arch Ophthalmol. 1977;95:608-612.
48. Hirose S, Ohno S, Matsuda H. HLA-Bw54 and glaucomatocyclitic crisis. Arch Ophthalmol. 1985;103:1837-1839.
49. Yamamoto S, Pavan-Langston D, Tada R, et al. Possible role of herpes simplex virus in the origin of Posner-Schlossman syndrome. Am J Ophthalmol. 1995;119:796-798.
50. Irak I, Katz BJ, Zabriskie NA, Zimmerman PL. Posner-Schlossman syndrome and nonarteritic anterior segment ischemic optic neuropathy. J Neuroophthalmol. 2003;23:264-267.
51. Kim R, Van Stavern G, Juzych M. Nonarteritic anterior ischemic optic neuropathy associated with acute glaucoma secondary to Posner-Schlossman syndrome. Arch Ophthalmol. 2003;121:127-128.
52. Burnstein Y, Shelton K, Higginbotham EJ. Glaucomatocyclitic crisis in a child. Am J Ophthalmol. 1998;126:136-137.
53. Teekhasaence C, Ritch R. Glaucomatocyclitic crisis in a child. Am J Ophthalmol. 1999;127:626-627.
54. Hollwich F. Clinical aspects and therapy of the Posner-Schlossman syndrome [article in German]. Klin Monatsbl Augenheilkd. 1978;172:736-744.
55. Martin TM, Smith JR, Rosenbaum JT. Anterior uveitis: current concepts of pathogenesis and interactions with spondyloarthropathies. Curr Opin Rheumatol. 2002;14:337-341.
56. Reveille JD, Arnett FC. Spondyloarthritis: update on pathogenesis and management. Am J Med. 2005;118:592-603.
57. Brown MA, Wordsworth BP, Reveille JD. Genetics of ankylosing spondylitis. Clin Exp Rheumatol. 2002;20(suppl):S543-S549.
58. Ekman P, Kirveskari J, Granfors K. Modification of disease outcome in Salmonella-infected patients by HLA-B27. Arthritis Rheum. 2000;43:1527-1534.
59. Dangoria NS, DeLay ML, Kingsbury DJ, et al. HLA-B27 mis-folding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum. J Biol Chem. 2002;277:23549-23468.
60. Bird LA, Peh CA, Kollnberger S, Elliott T, McMichael AJ, Bowness P. Lymphoblastoid cells express HLA-B27 homodimers both intracellularly and at the cell surface following endosomal recycling. Eur j Immunol. 2003;33:748-759.
61. Kollnberger S, Bird L, Sun MY, et al. Cell surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis Rheum. 2002;46:2972-2982.
62. Kuon W, Holzhütter Hg, Appel H, et al. Identification of HLA-B27 restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated diseases. J Immunol. 2001;167:4739-4746.
63. Dulphy N, Peyrat MA, Tieng V, et al. Common intra-articular T cell expansions in patients with reactive arthritis: identical beta-chain junctional sequences and cytotoxicity toward HLA-B27. J Immunol. 1999;162:3830-3839.
64. Leirisalo-Repo M, Turunen U, Stenman S, Helenius P, Seppälä K. High frequency of silent inflammatory bowel disease in spondyloarthropathy. Arthritis Rheum. 1994;37:23-31.
65. Chang JH, McCluskey PJ, Wakefield D. Acute anterior uveitis and HLA-B27. Surv Ophthalmol. 2005;50:364-388.
66. Feltkamp TE. Ophthalmological significance of HLA associated uveitis. Eye. 1990;4:839-844.
67. Mapstone R, Woodrow JC. HLA-27 and acute anterior uveitis. Br J Ophthalmol. 1975;59:270-275.
68. McCannel CA, Holland GN, Helm CJ, et al. Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group. Am J Ophthalmol. 1996;121:35-46.
69. Linssen A, Meenken C. Outcomes of HLA-B27-positive and HLA-B27-negative acute anterior uveitis. Am J Ophthalmol. 1995;120:351-361.
70. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002;61(suppl III):iii8-iii18.
71. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis: results from the German rheumatological database. J Rheumatol. 2000;27:613-622.
72. Brophy S, Pavy S, Lewis P, et al. Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. J Rheumatol. 2001;28:2667-2673.
73. Ritchlin C. Newer therapeutic approaches: spondyloarthritis and uveitis. Rheum Dis Clin North Am. 2006;32:75-90.
74. Brandt J, Khariouzov A, Listing J, et al. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol. 2004;3:531-538.
75. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53:18-23.
76. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med. 2004; 140:404-406.
77. Kiss S, Letko E, Qamruddin S, Baltatzis S, Foster CS. Long-term progression, prognosis, and treatment of patients with recurrent ocular manifestations of Reiter's syndrome. Ophthalmology. 2003;110:1764-1769.
78. Keat A. Reiter's syndrome and reactive arthritis in perspective. N Engl J Med. 1983;309:1606-1615.
79. Sieper J. Disease mechanisms in reactive arthritis. Curr Rheumatol Rep. 2004;16:110-116.
80. Amor B. Reiter's syndrome: diagnosis and clinical features. Rheum Dis Clin North Am. 1998;24:677-695.
81. Durrani K, Foster SC. Psoriatic uveitis: a distinct clinical entity? Am J Ophthalmol. 2005;139:106-111.
82. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55-78.
83. Lambert JR, Wright V. Eye inflammation in psoriatic arthritis. Ann Rheum Dis. 1976;35:354-356.
84. Paiva ES, Macaluso DC, Edwards A, Rosenbaum JT. Characterisation of uveitis in patients with psoriatic arthritis. Ann Rheum Dis. 2000;59:67-70.
85. Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol. 1997;115:61-64.
86. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116-1122.
87. Lin P, Tessler HH, Goldstein DA. Family history of inflammatory bowel disease in patients with idiopathic ocular inflammation. Am J Ophthalmol. 2006;141:1097-1104.
88. Pras E, Neumann R, Zandman-Goddard G, et al. Intraocular inflammation in autoimmune diseases. Semin Arthritis Rheum. 2004;34:602-609.
89. Van Bodegraven AA, Peña AS. Treatment of extraintestinal manifestations in inflammatory bowel disease. Curr Treat Options Gastroenterol. 2003;6:201-212.
90. Barrie A, Plevy S. Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease with infliximab. Gastroenterol Clin N Am. 2006;35:883-893.
91. Burns JC, Mason WH, Hanger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005;146:662-667.
92. Kawasaki T, Kosaki F, Okawa S, Shigemitsu L, Yanagawa S. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54:271-276.
93. Yanagawa H, Yashiro M, Nakamura Y, Hirose K, Kawasaki T. Nationwide surveillance of Kawasaki disease in Japan, 1984 to 1993. Pediatr Infect Dis J. 1995;14:69.
94. Burns JC, Capparelli EV, Brown JA, Newberger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/ Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J. 1998;17:1144-1148.
95. Chang FY, Hwang B, Chen SJ, Lee PC, Meng CCL, Lu JH. Characteristics of Kawasaki disease in infants younger than six months of age. Pediatr Infect Dis J. 2006;25:241-244.
96. Gocho K, Kondo T, Yamaki K. Identification of autroreactive T cells in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 2001;42:2004-2009.
97. Moorthy SR, Inomata H, Rao NA. Bogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995;39:265-292.
98. Yamaki K, Gocho K, Hayakawa K, Kondo I, Sakuragi S. Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol. 2000;165:7323-7329.
99. Nussenblatt R.B. Vogt-Koyanagi-Harada syndrome. In: Nussenblatt RB, Whitcup SM. Uveitis: Fundamentals and Clinical Practice, 3rd ed. 1989:324-338.
100. Rathinam SR, Vijayalakshmi P, Nanperumalsamy P, Nozik RA, Cunningham ET Jr. Vogt-Koyanagi-Harada syndrome in children. Ocul Immunol Inflamm. 1998;6:155-161.
101. Chan CC, Roberge RG, Whitcup SM, Nussenblatt RB. 32 cases of sympathetic ophthalmia: a retrospective study at the National Eye Institute, Bethesda, Md., from 1982 to 1992. Arch Ophthalmol. 1995;113:597-600. Erratum in: Arch Ophthalmol. 1995;113:1507.
102. Hammer H. Cellular hypersensitivity to uveal pigment confirmed by leukocyte migration tests in sympathetic ophthalmitis and the Vogt-Koyanagi-Harada syndrome. Br J Ophthalmol. 1974;58:773-776.
103. Shindo Y, Inoko H, Yamamoto T, Ohno S. HLA-DRB1 typing of Vogt-Koyanagi-Harada's disease by PCR-RFLP and the strong association with DRB1*0405 and DRB1*0410. Br J Ophthalmol. 1994; 78:223-236.
104. Shindo Y, Ohno S, Usui M, et al. Immunogenetic study of sympathetic ophthalmia. Tissue Antigens. 1997;49:111-115.
105. Kilmartin DJ, Wilson D, Liversidge J, et al. Immunogenetics and clinical phenotype of sympathetic ophthalmia in British and Irish patients. Br J Ophthalmol. 2001;85:281-286.
106. Lubin J, Albert D, Weinstein M. Sixty-five years of sympathetic ophthalmia: a clinicopathologic review of 105 cases (1913-1978). Ophthalmology. 1980;87:109-121.
107. Rathinam SR, Rao NA. Sympathetic ophthalmia following post-operative bacterial endophthalmitis: a clinicopathologic study. Am J Ophthalmol. 2006;141:498-507.
108. Perry HD, Font RL. Clinical and histopathologic observations in severe Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1977;83:242-245.
109. Font RL, Fine BS, Messmer E, Rowsey JF. Light and electron microscopy study of Dalen-Fuchs nodules in sympathetic ophthalmia. Ophthalmology. 1983;90:66-75.
110. Kilmartin DJ, Dick AD, Forrester JV. Prospective surveillance of sympathetic ophthalmia in the United Kingdom and Republic of Ireland. Br J Ophthalmol. 2000;84:259-263.
111. Rao NA, Robin J, Hartmann D, Sweeney JA, Marak GE Jr. The role of the penetrating wound in the development of sympathetic ophthalmia: experimental observations. Arch Ophthalmol. 1993;101:102-104.
112. Forrester JV. Uveitis: pathogenesis. Lancet, 1991;338:1498-1501.
113. Jonas JB. Intravitreal triamcinolone acetonide for treatment of sympathetic ophthalmia. Am J Ophthalmol. 2004;137:367-368.
114. Dobrin RS, Vernier RL, Fish AL. Acute eosinophilic interstitial nephritis and renal failure with bone marrow-lymph node granulomas and anterior uveitis: a new syndrome. Am J Med. 1975;59:325-333.
115. Mandeville JT, Levinson RD, Holland GN. The tubulointerstitial nephritis and uveitis syndrome. Surv Ophthalmol. 2001;46:195-208.
116. Goda C, Kotake S, Ichiishi A, Namba K, Kitaichi N, Ohno S. Clinical features in tubulointerstitial nephritis and uveitis (TINU) syndrome. Am J Ophthalmol. 2005;140:637-641.
117. Goda C, Kotake S, Sasamoto Y, et al. Review of uveitis in children in our institution. Jpn J Clin Ophthalmol. 1995;49:1595-1599.
118. Mackensen F, Smith JR, Rosenbaum JT. Enhanced recognition, treatment, and prognosis of tubulointerstitial nephritis and uveitis syndrome. Ophthalmology. 2007;114:995-999.
119. Sessa A, Meroni M, Battini G, Vigano G, Brambilla PL, Paties CT. Acute renal failure due to idiopathic tubulointerstitial nephritis and uveitis: "TINU syndrome" J Nephrol. 2000;13:377-380.
120. Azar R, Verove C, Boldron A. Delayed onset of uveitis in TINU syndrome. J Nephrol. 2000;13:381-383.
121. Noël C, Dracon M, Dhondt JL, et al. Acute interstitial nephritis and uveitis in the adult: apropos of 3 cases [article in French]. Nephrologie. 1986;7:195-197.
122. Guerriero S, Vischi A, Giancipoli G, Leozappa M, Ferrari TM. Tubulointerstitial nephritis and uveitis syndrome. J Pediatr Ophthalmol Strabismus. 2006;43:241-243.
123. Waeben M, Boven K, D'Heer B, Tassignon MJ. Tubulointerstitial-nephritis uveitis (TINU)-syndrome with posterior uveitis. Bull Soc Belge Ophtalmol. 1996;261:73-76.
124. Manjon MT, Sanchez-Burson J, Montero R, Perez-Pequena J, Alonso M, Marenco JL. Two cases of acute tubulointerstitial nephritis associated with panuveitis (TINU syndrome). J Rheumatol. 1999;26:234-236.
125. Levinson RD, Park MS, Rikkerrs SM, et al. Strong associations between specific HLA-DQ and HLA-DR alleles and the tubulointerstitial nephritis and uveitis syndrome. Invest Ophthalmol Vis Sci. 2003;44:653-657.
126. Gorroño-Echebarría MB, Calvo-Arrabal MA, Albarran F, Alvarez-Mon M. The tabulointerstitial nephritis and uveitis (TINU) syndrome is associated with HLA-DR14 in Spanish patients. Br J Ophthalmol. 2001;85:1010-1011.
127. Mochizuki M, Watanebe T, Yamaguchi K, et al. Human T-lymphotropic virus type1-associated disease. In: Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular Infection and Immunity. St. Louis: Mosby; 1996:1366-1387.
128. Thorne JE, Woreta F, Kedah SR, Dunn JP, Jabs DA. Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol. 2007;143:840-846.
129. Calibers P, Chabner BA. Chem2otherapy of neoplastic diseases. In: Gilman AG, Rally TW, Knies AS, Taylor P, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics. New York: Pergamon Press; 1990:1202-1263.
130. Hargraves MR, Mowat AG, Benson MK. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax. 1992;47:628-633.
131. Nussenblatt R, Palestine A. Cyclosporine: immunology, pharmacology, and therapeutic uses. Surv Ophthalmol. 1986;31:159-169.
132. Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S. Cyclosporine-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology. 1988;123:2571-2577.
133. Foster CS. Immunosuppressive therapy for external ocular inflammatory disease. Ophthalmology. 1980;87:140-150.
134. Brubaker R, Font RL, Shepherd EM. Granulomatous sclerouveitis, regression of ocular lesions with cyclophosphamide and prednisone. Arch Ophthalmol. 1971;86:517-524.
135. Nashel DJ. Mechanisms of action and clinical applications of cytotoxic drugs in rheumatic disorders. Med Clin North Am. 1985;69:817-840.
136. Reeves BR, Casey G, Leavitt R, Dinning WJ. Long-term cytogenetic follow-up study of patients with uveitis treated with chlorambucil. Carcinogenesis. 1985;6:1615-1619.
137. Nussenblatt RB, Whitcup SM. Uveitis: Fundamentals and Clinical Practice. Philadelphia: Mosby; 2004:108.
138. Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 2001;44:1411-1411.
139. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2006;91:319-324.
140. Gerloni V, Pontikaki I, Gattinara M, et al. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum. 2005;52:548-553.
141. Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113:2317-2323.
142. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr. 2006;149:572-575.
143. Li Z, Lim WK, Mahesh SP, Liu B, Nussenblatt RB. Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol. 2005;174:5187-5191. Erratum in: J Immunol. 2005;175:3447.
144. Nussenblatt RB, Fortin E, Schliffman R, et al. Treatment of non-infectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A. 1999;96:7462-7466.
145. Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology. 2003;110:786-789.
146. Fonollosa A, Segura A, Giralt J, Garcia-Arumi J. Tuberculous uveitis after treatment with etanercept. Graefes Arch Clin Exp Ophthalmol. 2007;245:1397-1399.
147. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565-2570.
148. Foroozan R, Buono LM, Sergott RC, Savino PJ. Retrobulbar optic neuritis associated with infliximab. Arch Ophthalmol. 2002;120:985-987.
149. Levy-Clarke GA, Nussenblatt RB, Smith JA. Management of chronic pediatric uveitis. Curr Opin Ophthalmol. 2005;16:281-288.
150. Ho CL, Wong EY, Walton DS. Goniosurgery for glaucoma complicating chronic childhood uveitis. Arch Ophthalmol. 2004;122:838-844.